Overview:

Summary

Pharmaceutical report, “ENT Disorders Market to 2016 - Increasing Resistance to Anti-Bacterials to Drive Development of Novel Therapies for ENT Disorders” provides in-depth analysis of unmet needs, drivers and barriers that impact the global ENT disorders market. The report analyzes the markets for ENT disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2016 for the key geographies as well as the leading therapeutic segments including tonsillitis, sinusitis, rhinitis and otitis media. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

GBI Research finds that the ENT disorders market will continue to grow marginally. The prime reasons for slow growth of the market are the generic domination and the weak product pipelines for all the four indications. In 2009, the ENT disorders market was estimated at $16.3 billion. GBI Research forecasts the market to grow at a compound annual growth rate (CAGR) of approximately 0.6% between 2009 and 2016.

Scope

- Annualized market data for the ENT disorders market from 2002 to 2009, forecast forward to 2016.
- Analysis of the leading therapeutic segments, including tonsillitis, sinusitis, rhinitis and otitis media.
- Analysis of the ENT disorders market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan.
- Market characterization of the ENT disorders market, including market size, annual cost of therapy and treatment usage patterns
- Key drivers and barriers that have a significant impact on the market
- Coverage of pipeline molecules in various phases of drug development
- Competitive benchmarking of leading companies. The key companies studied in this report are Abbott Laboratories, Astellas Pharma, Bayer AG, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Eli Lilly, GSK, J&J, Novartis AG, Sanofi-Aventis etc.
- Key M&A activities, licensing agreements that have taken place between 2004 and mid-2010 in the global ENT disorders market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.
- Develop key strategic initiatives by understanding the key focus areas of leading companies.
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.

Companies Mentioned

Abbott Laboratories
Bayer AG
Eli Lilly
GlaxoSmithKline
Johnson & Johnson (J&J)
Merck & Co
Pfizer
Novartis AG
F. Hoffmann-La Roche Ltd.
Sanofi-Aventis

1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 9
2 ENT Disorders Market: Introduction 11
2.1 GBI Research Report Guidance 11
3 ENT Disorders Market: Market Overview 12
3.1 Rising Global Population and Detrimental Environmental Conditions Drive ENT Disorder Therapeutics 12
3.2 Gross Maldistribution 12
3.3 Revenue Forecasts 13
3.4 Annual Cost of Therapy 14
3.5 Treatment Usage Patterns 15
3.5.1 Diseased Population 16
3.5.2 Treatment Seeking Population 17
3.5.3 Diagnosed Population 18
3.5.4 Prescription Population 19
3.6 Drivers and Restraints of the ENT Disorders Market 20
3.6.1 ENT Disorders Market Drivers 20
3.6.2 ENT Disorders Market Restraints 21
4 ENT Disorders Market: Therapeutic Landscape 22
4.1 Tonsillitis Market 22
4.1.1 Introduction 22
4.1.2 Revenue Forecasts 23
4.1.3 Annual Cost of Therapy 24
4.1.4 Treatment Usage Patterns 25
4.1.5 Profiles of Key Drugs in the Tonsillitis Market 29
4.1.6 Geographical Segmentation 30
4.2 Sinusitis Market 33
4.2.1 Introduction 33
4.2.2 Revenue Forecasts 34
4.2.3 Annual Cost of Therapy 35
4.2.4 Treatment Usage Patterns 36
4.2.5 Profiles of Key Drugs in the Sinusitis Market 41
4.2.6 Geographical Segmentation 42
4.3 Rhinitis Market 44
4.3.1 Introduction 44
4.3.2 Revenue Forecasts 45
4.3.3 Annual Cost of Therapy 46
4.3.4 Treatment Usage Patterns 47
4.3.5 Profiles of Key Drugs in the Rhinitis Market 53
4.3.6 Geographical Segmentation 54
4.4 Otitis Media Market 56
4.4.1 Introduction 56
4.4.2 Revenue Forecasts 57
4.4.3 Annual Cost of Therapy 58
4.4.4 Treatment Usage Patterns 59
4.4.5 Profiles of Key Drugs in the Otitis Media Market 64
4.4.6 Geographical Segmentation 64
5 ENT Disorders Market: Geographical Landscape 67
5.1 The US 69
5.1.1 Revenue Forecasts 69
5.1.2 Annual Cost of Therapy 70
5.1.3 Treatment Usage Patterns 71
5.2 Top Five Countries in Europe 76
5.2.1 Revenue Forecasts 76
5.2.2 Annual Cost of Therapy 77
5.2.3 Treatment Usage Patterns 78
5.3 Japan 84
5.3.1 Revenue Forecasts 84
5.3.2 Annual Cost of Therapy 85
5.3.3 Treatment Usage Patterns 86
6 ENT Disorders Market: Pipeline Analysis 91
6.1 Introduction 91
6.1.1 Research and Development Pipeline – Tonsillitis 92
6.1.2 Research and Development Pipeline – Sinusitis 93
6.1.3 Research and Development Pipeline – Rhinitis 95
6.1.4 Research and Development Pipeline – Otitis Media 96
6.1.5 Otitis Media –Drugs under Clinical Development 96
7 ENT Disorders Market: Competitive Landscape 98
7.1 Competitive Profiling 98
7.1.1 Abbott Laboratories 98
7.1.2 Bayer AG 99
7.1.3 Eli Lilly 100
7.1.4 GlaxoSmithKline 101
7.1.5 Johnson & Johnson (J&J) 102
7.1.6 Merck & Co 103
7.1.7 Pfizer 105
7.1.8 Novartis AG 106
7.1.9 F. Hoffmann-La Roche Ltd. 107
7.1.10 Sanofi-Aventis 108
8 ENT Disorders Market: Strategic Consolidations 110
8.1 Overview 110
8.2 ENT Disorders Market M&A Deals 110
8.2.1 M&A Deals by Geography 111
8.2.2 Deals by Type 112
8.2.3 Major M&A Deals 112
8.3 R&D Licensing Agreements 114
8.3.1 Orbus Pharma Entered Into Licensing Agreement with Dansk Laegemiddelforsyning in May 2007 114
8.3.2 Orbus Pharma Entered into Licensing Agreement with DAA Pharma – December 2006 114
8.3.3 Accentia Biopharmaceuticals Amends Licensing Agreement with Mayo Foundation in August 2006 115
8.3.4 OctoPlus Expanded its Licensing Agreement with Leiden University in July 2006 115
8.3.5 Orbus Pharma Entered Into Licensing Agreement with Generics UK in September 2005 115
8.3.6 Orbus Pharma Entered Into Licensing Agreement with Teva Generics Belgium in July 2005 115
8.3.7 Accentia BioPharmaceuticals Entered into Licensing Agreement with BioDelivery Sciences International in April 2004 115
9 ENT Disorders Market: Appendix 116
9.1 Market Definitions 116
9.2 Abbreviations 116
9.3 Research Methodology 117
9.3.1 Coverage 117
9.3.2 Secondary Research 117
9.3.3 Primary Research 117
9.3.4 Forecasts 118
9.3.5 Expert Panel Validation 120
9.4 Contact Us 120
9.5 Disclaimer 120
9.6 Sources 120

1.1 List of Tables
Table 1: ENT Disorders Market, Global, Revenue ($bn), 2002–2009 13
Table 2: ENT Disorders Market, Global, Revenue Forecasts ($bn), 2009–2016 13
Table 3: ENT Disorders Market, Global, Annual Cost of Therapy ($), 2002–2009 14
Table 4: ENT Disorders Market, Global, Annual Cost of Therapy ($), 2009–2016 14
Table 5: ENT Disorders Market, Global, Treatment Usage Patterns (million), 2002–2009 15
Table 6: ENT Disorders Market, Global, Treatment Usage Patterns (million), 2009–2016 16
Table 7: ENT Disorders Market, Global, Tonsillitis Revenues ($m), 2002–2009 23
Table 8: ENT Disorders Market, Global, Tonsillitis Revenue Forecasts ($m), 2009–2016 23
Table 9: ENT Disorders Market, Global, Tonsillitis Annual Cost of Therapy ($), 2002–2009 24
Table 10: ENT Disorders Market, Global, Tonsillitis Annual Cost of Therapy ($), 2009–2016 24
Table 11: ENT Disorders Market, Global, Tonsillitis Treatment Usage Patterns (million), 2002–2009 25
Table 12: ENT Disorders Market, Global, Tonsillitis Treatment Usage Patterns (million), 2009–2016 26
Table 13: ENT Disorders Market, Global, Tonsillitis Market Geographical Segmentation ($m), 2002–2009 32
Table 14: ENT Disorders Market, Global, Tonsillitis Market Geographical Segmentation ($m), 2009–2016 32
Table 15: ENT Disorders Market, Global, Sinusitis Revenues ($bn), 2002–2009 34
Table 16: ENT Disorders Market, Global, Sinusitis Revenue Forecasts ($bn), 2009–2016 34
Table 17: ENT Disorders Market, Global, Sinusitis Annual Cost of Therapy ($), 2002–2009 35
Table 18: ENT Disorders Market, Global, Sinusitis Annual Cost of Therapy ($), 2009–2016 35
Table 19: ENT Disorders Market, Global, Sinusitis Treatment Usage Patterns (million), 2002–2009 36
Table 20: ENT Disorders Market, Global, Sinusitis Treatment Usage Patterns (million), 2009–2016 36
Table 21: ENT Disorders Market, Global, Sinusitis Market Geographical Segmentation ($bn), 2002–2009 44
Table 22: ENT Disorders Market, Global, Sinusitis Market Geographical Segmentation, 2009–2016 44
Table 23: ENT Disorders Market, Global, Rhinitis Revenues ($bn), 2002–2009 45
Table 24: ENT Disorders Market, Global, Rhinitis Revenue Forecasts ($bn), 2009–2016 45
Table 25: ENT Disorders Market, Global, Rhinitis Annual Cost of Therapy ($), 2002–2009 46
Table 26: ENT Disorders Market, Global, Rhinitis Annual Cost of Therapy ($), 2009–2016 46
Table 27: ENT Disorders Market, Global, Rhinitis Treatment Usage Patterns (million), 2002–2009 47
Table 28: ENT Disorders Market, Global, Rhinitis Treatment Usage Patterns (million), 2009–2016 48
Table 29: ENT Disorders Market, Global, Rhinitis Market Geographical Segmentation ($bn), 2002–2009 56
Table 30: ENT Disorders Market, Global, Rhinitis Market Geographical Segmentation ($bn), 2009–2016 56
Table 31: ENT Disorders Market, Global, Otitis Media Revenues ($m), 2002–2009 57
Table 32: ENT Disorders Market, Global, Otitis Media Revenue Forecasts ($m), 2009–2016 57
Table 33: ENT Disorders Market, Global, Otitis Media Annual Cost of Therapy ($), 2002–2009 58
Table 34: ENT Disorders Market, Global, Otitis Media Annual Cost of Therapy ($), 2009–2016 58
Table 35: ENT Disorders Market, Global, Otitis Media Treatment Usage Patterns (million), 2002–2009 59
Table 36: ENT Disorders Market, Global, Otitis Media Treatment Usage Patterns (million), 2009–2016 59
Table 37: ENT Disorders Market, Global, Otitis Media Market Geographical Segmentation ($m), 2002–2009 66
Table 38: ENT Disorders Market, Global, Otitis Media Market Geographical Segmentation ($m), 2009–2016 66
Table 39: ENT Disorders Market, Global, Revenues by Geography ($bn), 2002–2009 68
Table 40: ENT Disorders Market, Global, Revenue Forecasts by Geography ($bn), 2009–2016 68
Table 41: ENT Disorders Market, The US, Revenues ($bn), 2002–2009 69
Table 42: ENT Disorders Market, The US, Revenue Forecasts ($bn), 2009–2016 69
Table 43: ENT Disorders Market, The US, Annual Cost of Therapy ($), 2002–2009 70
Table 44: ENT Disorders Market, The US, Annual Cost of Therapy ($), 2009–2016 70
Table 45: ENT Disorders Market, The US, Treatment Usage Pattern (million), 2002–2009 71
Table 46: ENT Disorders Market, The US, Treatment Usage Pattern (million), 2009–2016 72
Table 47: ENT Disorders Market, Top Five Countries in Europe, Revenues ($bn), 2002–2009 76
Table 48: ENT Disorders Market, Top Five Countries in Europe, Revenue Forecasts ($bn), 2009–2016 76
Table 49: ENT Disorders Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2002–2009 77
Table 50: ENT Disorders Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2009–2016 77
Table 51: ENT Disorders Market, Top Five Countries in Europe, Treatment Usage Pattern (million), 2002–2009 78
Table 52: ENT Disorders Market, Top Five Countries in Europe, Treatment Usage Pattern (million), 2009–2016 79
Table 53: ENT Disorders Market, Japan, Revenues ($bn), 2002–2009 84
Table 54: ENT Disorders Market, Japan, Revenue Forecasts ($bn), 2009–2016 84
Table 55: ENT Disorders Market, Japan, Annual Cost of Therapy ($), 2002–2009 85
Table 56: ENT Disorders Market, Japan, Annual Cost of Therapy ($), 2009–2016 85
Table 57: ENT Disorders Market, Japan, Treatment Usage Pattern (million), 2002–2009 86
Table 58: ENT Disorders Market, Japan, Treatment Usage Pattern (million), 2009–2016 86
Table 59: Otitis Media, Pre-Clinical Pipeline, December 2010 96
Table 60: Otitis Media, Phase II Pipeline, December 2010 96
Table 61: Otitis Media, Phase III Pipeline, December 2010 97

1.2 List of Figures
Figure 1: ENT Disorders Market, Global, Revenue Forecasts ($bn), 2002–2016 13
Figure 2: ENT Disorders Market, Global, Annual Cost of Therapy ($), 2002–2016 14
Figure 3: ENT Disorders Market, Global, Treatment Usage Pattern (million), 2002–2016 15
Figure 4: ENT Disorders Market, Global, Diseased Population (million), 2002–2016 16
Figure 5: ENT Disorders Market, Global, Treatment Seeking Population (million), 2002–2016 17
Figure 6: ENT Disorders Market, Global, Diagnosis Population (million), 2002–2016 18
Figure 7: ENT Disorders Market, Global, Prescription Population (million), 2002–2016 19
Figure 8: ENT Disorders Market, Global, Drivers and Restraints, 2009 20
Figure 9: ENT Disorders Market, Global, Tonsillitis Revenue Forecasts ($m), 2002–2016 23
Figure 10: ENT Disorders Market, Global, Tonsillitis Annual Cost of Therapy ($), 2002–2016 24
Figure 11: ENT Disorders Market, Global, Tonsillitis Treatment Usage Patterns (million), 2002–2016 25
Figure 12: ENT Disorders Market, Global, Tonsillitis Diseased Population (million), 2002–2016 26
Figure 13: ENT Disorders Market, Global, Tonsillitis Treatment Seeking Population (million), 2002–2016 27
Figure 14: ENT Disorders Market, Global, Tonsillitis Diagnosis Population (million), 2002–2016 28
Figure 15: ENT Disorders Market, Global, Tonsillitis Prescription Population (million), 2002–2016 29
Figure 16: ENT Disorders Market, Global, Tonsillitis Market Segmentation by Geography, 2009 and 2016 30
Figure 17: ENT Disorders Market, Global, Tonsillitis Market in the Top Five Countries in Europe, 2009 and 2016 31
Figure 18: ENT Disorders Market, Global, Tonsillitis Market Geographical Segmentation ($m), 2002–2016 31
Figure 19: ENT Disorders Market, Global, Sinusitis Revenue Forecasts ($bn), 2002–2016 34
Figure 20: ENT Disorders Market, Global, Sinusitis Annual Cost of Therapy ($), 2002–2016 35
Figure 21: ENT Disorders Market, Global, Sinusitis Treatment Usage Patterns (million), 2002–2016 36
Figure 22: ENT Disorders Market, Global, Sinusitis Diseased Population (million), 2002–2016 37
Figure 23: ENT Disorders Market, Global, Sinusitis Treatment Seeking Population (million), 2002–2016 38
Figure 24: ENT Disorders Market, Global, Sinusitis Diagnosed Population (million), 2002–2016 39
Figure 25: ENT Disorders Market, Global, Sinusitis Prescription Population (million), 2002–2016 40
Figure 26: ENT Disorders Market, Global, Sinusitis Market Segmentation by Geography, 2009 and 2016 42
Figure 27: ENT Disorders Market, Global, Sinusitis Market in the Top Five Countries in Europe, 2009 and 2016 43
Figure 28: ENT Disorders Market, Global, Sinusitis Market Geographical Segmentation ($bn), 2002–2016 43
Figure 29: ENT Disorders Market, Global, Rhinitis Revenue Forecasts ($bn), 2002–2016 45
Figure 30: ENT Disorders Market, Global, Rhinitis Annual Cost of Therapy ($), 2002–2016 46
Figure 31: ENT Disorders Market, Global, Rhinitis Treatment Usage Patterns (million), 2002–2016 47
Figure 32: ENT Disorders Market, Global, Rhinitis Diseased Population (million), 2002–2016 49
Figure 33: ENT Disorders Market, Global, Rhinitis Treatment Seeking Population (million), 2002–2016 50
Figure 34: ENT Disorders Market, Global, Rhinitis Diagnosis Population (million), 2002–2016 51
Figure 35: ENT Disorders Market, Global, Rhinitis Prescription Population (million), 2002–2016 52
Figure 36: ENT Disorders Market, Global, Rhinitis Market Segmentation by Geography, 2009 and 2016 54
Figure 37: ENT Disorders Market, Global, Rhinitis Market in the Top Five Countries in Europe, 2009 and 2016 55
Figure 38: ENT Disorders Market, Global, Rhinitis Market Geographical Segmentation ($bn), 2002–2016 55
Figure 39: ENT Disorders Market, Global, Otitis Media Revenue Forecasts ($m), 2002–2016 57
Figure 40: ENT Disorders Market, Global, Otitis Media Annual Cost of Therapy ($), 2002–2016 58
Figure 41: ENT Disorders Market, Global, Otitis Media Treatment Usage Patterns (million), 2002–2016 59
Figure 42: ENT Disorders Market, Global, Otitis Media Diseased Population (million), 2002–2016 60
Figure 43: ENT Disorders Market, Global, Otitis Media Treatment Seeking Population (million), 2002–2016 61
Figure 44: ENT Disorders Market, Global, Otitis Media Diagnosed Population (million), 2002–2016 62
Figure 45: ENT Disorders Market, Global, Otitis Media Prescription Population (million), 2002–2016 63
Figure 46: ENT Disorders Market, Global, Otitis Media Market Segmentation by Geography, 2009 and 2016 64
Figure 47: ENT Disorders Market, Global, Otitis Media Market in the Top Five Countries in Europe (%), 2009 and 2016 65
Figure 48: ENT Disorders Market, Global, Otitis Media Market Geographical Segmentation ($m), 2002–2016 65
Figure 49: ENT Disorders Market, Global, Market Share by Geography, 2009 and 2016 67
Figure 50: ENT Disorders Market, Global, Revenue Forecasts by Geography ($bn), 2002–2016 67
Figure 51: ENT Disorders Market, The US, Revenue Forecasts ($bn), 2002–2016 69
Figure 52: ENT Disorders Market, The US, Annual Cost of Therapy ($), 2002–2016 70
Figure 53: ENT Disorders Market, The US, Treatment Usage Pattern (million), 2002–2016 71
Figure 54: ENT Disorders Market, The US, Diseased Population (million), 2002–2016 72
Figure 55: ENT Disorders Market, The US, Treatment Seeking Population (million), 2002–2016 73
Figure 56: ENT Disorders Market, The US, Diagnosed Population (million), 2002–2016 74
Figure 57: ENT Disorders Market, The US, Prescription Population (million), 2002–2016 75
Figure 58: ENT Disorders Market, Top Five Countries in Europe, Revenue Forecasts ($bn), 2002–2016 76
Figure 59: ENT Disorders Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2002–2016 77
Figure 60: ENT Disorders Market, Top Five Countries in Europe, Treatment Usage Patterns (million), 2002–2016 78
Figure 61: ENT Disorders Market, Top Five Countries in Europe, Diseased Population (million), 2002–2016 80
Figure 62: ENT Disorders Market, Top Five Countries in Europe, Treatment Seeking Population (million), 2002–2016 81
Figure 63: ENT Disorders Market, Top Five Countries in Europe, Diagnosed Population (million), 2002–2016 82
Figure 64: ENT Disorders Market, Top Five Countries in Europe, Prescription Population (million), 2002–2016 83
Figure 65: ENT Disorders Market, Japan, Revenues ($m), 2002–2016 84
Figure 66: ENT Disorders Market, Japan Annual Cost of Therapy, ($), 2002–2016 85
Figure 67: ENT Disorders Market, Japan, Treatment Usage Pattern (million), 2002–2016 86
Figure 68: ENT Disorders Market, Japan, Diseased Population (million), 2002–2016 87
Figure 69: ENT Disorders Market, Japan, Treatment Seeking Population (million), 2002–2016 88
Figure 70: ENT Disorders Market, Japan, Diagnosis Population (million), 2002–2016 89
Figure 71: ENT Disorders Market, Japan, Prescription Population (million), 2002–2016 90
Figure 72: ENT Disorders Market, Global, R&D Pipeline by Indication (%), December 2010 91
Figure 73: ENT Disorders Market, Global, R&D Pipeline by Phase (%), December 2010 92
Figure 74: ENT Disorders Market, Global, R&D Pipeline by Phase in Sinusitis Market (%), December 2010 93
Figure 75: ENT Disorders Market, Global, R&D Pipeline by Phase in Rhinitis Market (%), December 2010 95
Figure 76: ENT Disorders Market, Global, R&D Pipeline by Phase in Otitis Media (%), December 2010 96
Figure 77: ENT Disorders Market, Global, SWOT - Abbott Laboratories, 2010 98
Figure 78: ENT Disorders Market, Global, SWOT - Bayer AG, 2010 99
Figure 79: ENT Disorders Market, Global, SWOT - Eli Lilly, 2010 100
Figure 80: ENT Disorders Market, Global, SWOT - GSK, 2010 102
Figure 81: ENT Disorders Market, Global, SWOT - Johnson & Johnson, 2010 103
Figure 82: ENT Disorders Market, Global, SWOT - Merck, 2010 104
Figure 83: ENT Disorders Market, Global, SWOT - Pfizer, 2010 105
Figure 84: ENT Disorders Market, Global, SWOT - Novartis, 2010 106
Figure 85: ENT Disorders Market, Global, SWOT - Roche, 2010 108
Figure 86: ENT Disorders Market, Global, SWOT - Sanofi, 2010 109
Figure 87: ENT Disorders Market, Global, M&A Deals by Indication (%), 2009-2010 110
Figure 88: ENT Disorders Market, Global, Major M&A Deals By Geography (%), 2004–2010 111
Figure 89: ENT Disorders Market, Global, Major M&A Deals By Type (%), 2004–2010 112
Figure 90: GBI Research Market Forecasting Model 119